Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Trial Profile

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPONSE
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 12 Oct 2017 Results of data from patients of this study to demonstrate modelled survival, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 01 Jul 2017 Results of post hoc exploratory analysis of the RESPONSE trial assessing the effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden to explore the relationship between allele burden changes and clinical outcomespublished in the Annals of Hematology
    • 18 Feb 2016 According to Novartis Pharmaceuticals media release, Health Canada has approved Jakavi (ruxolitinib), for the control of hematocrit in adult patients with polycythemia vera (PV) resistant to or intolerant of a cytoreductive agent.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top